The drug was developed by Eli Lilly, and it can slow by one-third the rate of formation of white plaques in the brain that lead to cognitive decline. The six-month therapy will cost $12,500.
The drug donanemab (to be marketed under the brand name Kisunla) from Eli Lilly Pharmaceutical Corporation has received approval from the US Food and Drug Administration (FDA).
The new drug should lead to a reduction in the concentration of abnormal amyloid proteins in the brain, which led to a sharp and significant deterioration of cognitive function. The cause of these proteins is still not understood, but the new drug can stop the development of the disease. Clinical trials have shown a 35% slowdown in the formation of these proteins.
Russian scientists have developed an implant that can safely close diaphragmatic hernia.
The Russian Academy of Sciences said that the death rate from malignant cancerous tumors has decreased in Russia.